Genotype-phenotype correlation in multiple endocrine neoplasia type 1
JCI Insight · 24.03.2025 · 10 (6)
DOI: 10.1172/jci.insight.176993 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, online erschienen am 13.02.2025. Verfasst von Charlita C Worthy und 14 weiteren Autor:innen. Beteiligte Einrichtung: Metabolic Diseases Branch. Hauptthemen laut MEDLINE: Multiple Endocrine Neoplasia Type 1, Proto-Oncogene Proteins. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, Intramural NIH HHS, NIDDK, NIH.
Abstract (Originalsprache)
BACKGROUND Among patients with multiple endocrine neoplasia type 1 (MEN1), 80% develop duodenopancreatic neuroendocrine tumors (dpNETs), of whom 15%–25% die of metastasis. There is a need to identify biomarkers to predict aggressive disease. MEN1 genotype affords an attractive possibility as a biomarker, as it remains constant during life. Currently, patients are clinically diagnosed with MEN1 by the presence of ≥2 primary endocrine tumors (pituitary, parathyroid, and pancreas) or ≥1 primary endocrine tumor with a positive family history. From 10% to 30% of patients diagnosed clinically with MEN1 have no pathogenic germline MEN1 variants. METHODS This was a retrospective study of 162 index patients or probands with genotype-positive and 47 with genotype-negative MEN1 enrolled from 1977 to 2022. RESULTS Compared with patients with genotype-negative disease, patients with genotype-positive disease were younger at diagnosis and had an increased frequency of recurrent parathyroid tumors, dpNETs, and angiofibromas or collagenomas. We propose a weighted scoring system to diagnose genotype-positive MEN1 based on clinical characteristics. No evidence of MEN1 mosaicism was seen in 30 tumors from 17 patients with genotype-negative MEN1. Patients with germline MEN1 variants in exons 2 and 3 had a reduced risk of distant metastases. CONCLUSION The clinical course of genotype-negative MEN1 is distinct from genotype-positive disease, raising uncertainty about the benefits of lifetime surveillance in patients with genotype-negative disease. MEN1 mosaicism is rare. TRIAL REGISTRATION ClinicalTrials.gov NCT04969926 FUNDING Intramural Research Program of National Institute of Diabetes and Digestive and Kidney Diseases, NIH (ZIA DK043006-46)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Metabolic Diseases Branch.
- Digestive Diseases Branch, and.
- Biostatistics Program, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland, USA.
Förderung
- NCATS NIH HHS
- Intramural NIH HHS
- NIDDK, NIH
Zitieren
APA
Worthy, C. C., Tora, R., Uttarkar, C. N., Welch, J. M., Bliss, L., Cochran, C., Ninan, A., Kumar, S., Wank, S., Auh, S., Weinstein, L. S., Simonds, W. F., Agarwal, S. K., Blau, J. E., & Jha, S. (2025). Genotype-phenotype correlation in multiple endocrine neoplasia type 1. JCI Insight, 10(6). https://doi.org/10.1172/jci.insight.176993
Vancouver
Worthy CC, Tora R, Uttarkar CN, Welch JM, Bliss L, Cochran C, et al. Genotype-phenotype correlation in multiple endocrine neoplasia type 1. JCI Insight. 2025;10(6). doi:10.1172/jci.insight.176993
BibTeX
@article{Worthy2025,
author = {Worthy, Charlita C and Tora, Rana and Uttarkar, Chandra N and Welch, James M and Bliss, Lynn and Cochran, Craig and Ninan, Anisha and Kumar, Sheila and Wank, Stephen and Auh, Sungyoung and Weinstein, Lee S and Simonds, William F and Agarwal, Sunita K and Blau, Jenny E and Jha, Smita},
title = {Genotype-phenotype correlation in multiple endocrine neoplasia type 1},
journal = {JCI Insight},
year = {2025},
volume = {10},
number = {6},
doi = {10.1172/jci.insight.176993}
}
EUVIMED